Inhibition of rennin angiotensin aldosterone system and nephroprotection
On the basis of analysis of main multicenter trials discusses the mechanisms of nephro and cardioprotection of angiotesin Iconverting enzime (ACE) inhibitors and blockers receptors of angiotensin, whose use for treatment of cardiac patients and patients with diabetic and nondiabetic nephropathies is constantly increasing, but in some situations the appointment of renninangiotensin aldosterone system (RAAS) blockers unpromising. In elderly patients with high cardiovascular risk use of ACE inhibitors and blockers receptors of angiotensin, especially in combined form, is associated with development of serious complications, including decrease renal function.